Helixgate https://validator.w3.org/feed/docs/rss2.html Home Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options STAT+: Why Marty Makary was the worst FDA commissioner in 25 years AAVs in Focus: Practical Approaches to Capsid Analytics and Plasmid DNA Control Males who discuss suicide seek help less often than females, report finds Acute Myeloid Leukemia Therapy Improved by CRISPR Stem Cell Transplant FDA chief Marty Makary resigns from agency, ending tumultuous tenure FDA’s Makary to resign after Secretary Kennedy signs off EU reaches provisional deal on Critical Medicines Act STAT+: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in FDA Commissioner Makary to resign, source says What I learned at a journalism fellowship about covering healthcare AI Supreme Court extends mifepristone deadline Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis Five burning Qs for Isomorphic Labs after $2.1B raise for AI biotech Pfizer and Arvinas give disappointing breast cancer drug to Rigel STAT+: STAT examines America’s deadliest drug Bayer to make ‘careful but aggressive’ return to pharma M&A, CEO says Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge Introducing Benchling Biologics: AI infrastructure for modern drug discovery (Americas Session) Knit Health raises $11.6M for ‘fundamentally different’ approach to healthcare AI BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal STAT+: Capsida says it still doesn’t know what caused gene therapy death  BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival FDA turns to old drugs to address new diseases, persistent medical needs Scientists say this algae could remove microplastics from drinking water A year after Vertex’s big launch, pain drug research faces a pivotal moment Flagship startup, Serif, says it has solved non-viral gene therapy in monkeys STAT+: In the battle of sepsis algorithms, performance alone doesn’t predict victory Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B PCOS’s new name is PMOS, a small letter change that required a big scientific process STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs Stable Producer Cell Line Generation Platform Adds to VIVEbiotech’s Lentiviral Vector Manufacturing Capabilities Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed Cholesterol Drug May Weaken Ovarian Cancer’s Metastatic Defense Supreme Court temporarily extends women’s access to a widely used abortion pill Optum Rx unveils pharmacy model with clear fees, building on transparency push How HIV-1 Develops Resistance to Broadly Neutralizing Antibodies Rezdiffra is exceeding Wall Street’s expectations as the MASH market takes shape STAT+: Trump pivots on kratom derivative 7-OH, floating approval for some forms No FDA permission, no problem: New flavored vape policy worries experts Congress extends Rare Pediatric Disease Priority Review Voucher programme through 2029 GSK cuts deal with Sino to broaden reach of hepatitis B drug Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push New home for Novo’s Parkinson’s cell therapy; GSK turns to China for hep B drug RegVelo AI Model Predicts Cell Fate, Tackles Developmental Disorders and Cancer STAT+: Astellas treatment offers new hope to a devastated rare disease community Braveheart Bio’s Hengrui-licensed cardiac drug scores second clinical win Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls Biotech layoffs are easing, but is the worst over?